골수이형성증후군 시장 : 제품 유형, 치료 라인, 치료법, 투여 경로, 최종사용자, 유통 채널별 - 세계 예측(2026-2032년)

The Myelodysplastic Syndrome Market is projected to grow by USD 5.23 billion at a CAGR of 8.42% by 2032.

Myelodysplastic syndrome, commonly abbreviated as MDS, is a group of clonal hematopoietic stem cell disorders characterized by ineffective blood cell production, persistent cytopenias, bone marrow dysplasia, and variable risk of progression to acute myeloid leukemia. The disease burden is concentrated in older adults, with population-based studies commonly reporting incidence near 4 cases per 100,000 people annually and substantially higher rates among people over age 70.

The myelodysplastic syndrome market is being reshaped by better molecular classification, expanded anemia treatment options, and increasing use of next-generation sequencing in routine hematology care. Clinical decision-making now relies on integrated risk models, including IPSS-R and the molecularly informed IPSS-M, while treatment selection continues to split between lower-risk MDS focused on transfusion independence and higher-risk MDS focused on survival, AML prevention, and transplant eligibility.

Transformative Shifts in the MDS Treatment Landscape

The MDS landscape is shifting from morphology-led diagnosis toward integrated genomic, cytogenetic, and clinical risk assessment. The 2022 WHO and International Consensus Classification updates reinforced the importance of genetic lesions, such as SF3B1 mutation and biallelic TP53 inactivation, in defining disease entities and prognosis. This is increasing demand for molecular diagnostics, measurable residual disease research, and specialized hematopathology services.

Therapeutic change is also accelerating. Established options such as erythropoiesis-stimulating agents, lenalidomide for del(5q) lower-risk MDS, hypomethylating agents, and allogeneic hematopoietic stem cell transplantation are now complemented by newer anemia-directed therapies, including luspatercept and imetelstat for selected lower-risk transfusion-dependent patients. These shifts are expanding opportunities across supportive care, targeted hematology, transplant pathways, and real-world evidence generation.

Cumulative Impact of Artificial Intelligence in MDS

Artificial intelligence is having a cumulative impact across MDS discovery, diagnosis, and care delivery by improving the interpretation of complex datasets. AI-enabled image analysis can support bone marrow morphology review, while machine learning models applied to genomic, cytogenetic, laboratory, and clinical variables may improve risk stratification beyond conventional scoring when validated in diverse cohorts.

The most immediate value is operational and clinical: faster identification of trial-eligible patients, automated extraction of transfusion dependence from electronic health records, prediction of treatment response, and pharmacovigilance using real-world data. For industry leaders, AI will be most credible when combined with transparent model governance, bias testing across age and ancestry groups, and clinical validation against endpoints such as overall survival, AML transformation, transfusion independence, and quality of life.

Key Regional Insights for Myelodysplastic Syndrome

North America leads adoption of advanced MDS diagnostics and novel therapies, supported by dense hematology networks, high use of next-generation sequencing, clinical trial access, and established reimbursement pathways for oncology innovation. Europe shows strong clinical guideline alignment, hematopathology expertise, and trial participation, although access varies across national health technology assessment systems and hospital procurement models. Asia-Pacific is expanding rapidly as Japan, China, South Korea, Australia, and India strengthen hematology infrastructure, genomic testing capacity, registries, and access to specialty oncology medicines.

Latin America demonstrates rising diagnosis and treatment demand, led by Brazil and Mexico, but faces uneven access to molecular testing, transfusion services, hypomethylating agents, and transplant centers. The Middle East is investing in tertiary cancer centers, particularly in GCC countries, with growing reliance on specialist hematology, genomic medicine, and cross-border referral models. Africa remains constrained by late diagnosis, limited hematopathology capacity, variable blood product availability, and low access to allogeneic transplantation. Across all regions, aging populations, improved recognition of unexplained cytopenias, and broader use of bone marrow and molecular workups are increasing the diagnosed MDS patient pool.

Key Group Insights for Myelodysplastic Syndrome

Within ASEAN, MDS care is expanding through stronger tertiary hospitals in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines, but access to next-generation sequencing, specialist hematopathology, reimbursed novel therapies, and transplant remains uneven. The GCC is building advanced hematology capacity through public health investment and specialist medical centers in Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman, creating opportunities for molecular diagnostics, transfusion optimization, and innovative therapies for lower-risk and higher-risk MDS.

The European Union benefits from centralized regulatory science, multinational clinical trials, structured pharmacovigilance, and robust hematology societies, while BRICS countries present a high-volume opportunity shaped by China and India's large aging populations, Brazil's oncology infrastructure, Russia's specialist networks, and South Africa's regional referral role. G7 countries drive much of the high-value innovation through research funding, regulatory approvals, guideline adoption, and payer evaluation frameworks. NATO members overlap significantly with advanced Western healthcare markets, reinforcing supply-chain resilience, collaborative clinical research, and preparedness for critical medicines and blood product continuity in hematology care.

Key Country Insights for Myelodysplastic Syndrome

The United States remains the largest innovation hub for MDS treatment, supported by FDA-approved therapies, guideline-driven care, Medicare coverage for older adults, molecular testing uptake, and broad clinical trial activity. Canada emphasizes evidence-based reimbursement and specialist hematology access, while Mexico and Brazil are expanding diagnosis, transfusion support, and oncology infrastructure despite regional disparities. In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong hematology expertise, established treatment pathways, and active participation in clinical research, while Russia has significant specialist capacity with access shaped by procurement, regional policy, and availability of advanced diagnostics.

China is scaling oncology infrastructure, genomic testing, and domestic clinical research quickly, while India offers large unmet need with growing private and public hematology capacity and variable access to bone marrow diagnostics, blood products, and transplant services. Japan has a mature, aging-population-driven MDS care model with strong clinical research and high awareness of cytopenias in older adults. Australia provides high-quality hematology care through centralized referral systems and evidence-based reimbursement processes, while South Korea combines advanced diagnostics, strong biomedical research activity, and high digital health adoption. Country-level success depends on early diagnosis, transfusion access, molecular testing, specialist referral, and reimbursement for newer anemia-directed and disease-modifying therapies.

Actionable Recommendations for MDS Industry Leaders

Industry leaders should prioritize evidence generation that reflects real MDS treatment decisions, including transfusion independence, hematologic improvement, AML transformation, overall survival, adverse event burden, iron overload, hospital utilization, and patient-reported fatigue. Commercial strategies should segment lower-risk MDS, higher-risk MDS, del(5q) disease, SF3B1-mutated disease, TP53-altered disease, ring sideroblast-positive disease, and transplant-eligible populations rather than treating MDS as a single market.

Organizations should invest in companion-ready diagnostics, real-world data partnerships, clinical trial diversity, and payer evidence demonstrating reduced transfusion burden and hospital utilization. Success will increasingly depend on integrated offerings that connect molecular testing, therapy selection, response monitoring, adverse event management, and long-term patient support in both academic and community hematology settings.

Research Methodology

This executive assessment is built from verified clinical, regulatory, epidemiological, and market-access inputs, including disease classification standards, approved therapy labels, hematology guidelines, peer-reviewed evidence, public health sources, and publicly available health system information. The methodology emphasizes triangulation across clinical trial endpoints, real-world treatment patterns, diagnostic adoption, regulatory status, and regional healthcare capacity.

Insights are organized to support strategic decision-making in the myelodysplastic syndrome market without using market sizing, market share, or forecasting assumptions. Findings were evaluated through therapeutic area segmentation, regional access mapping, technology impact assessment, and policy review, with particular attention to lower-risk and higher-risk MDS, transfusion dependence, genomic testing adoption, transplant pathways, and the role of AI-enabled evidence generation.

Conclusion

The myelodysplastic syndrome market is entering a more precise and competitive phase as molecular classification, anemia-directed innovation, hypomethylating strategies, supportive care, and transplant pathways converge. Aging populations, improved cytopenia workups, and broader next-generation sequencing access are increasing diagnosed prevalence and sharpening demand for tailored treatments.

The strongest opportunities will emerge for organizations that combine clinically meaningful therapies with validated diagnostics, payer-relevant outcomes, real-world evidence, and region-specific access strategies. As AI, genomic medicine, and data-driven hematology mature, MDS care is expected to become more personalized, measurable, and outcome-driven across global hematology markets.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Myelodysplastic Syndrome Market, by Product Type

• 7.1. Branded
• 7.2. Generic

8. Myelodysplastic Syndrome Market, by Therapy Line

• 8.1. First Line
• 8.2. Second Line
• 8.3. Third Line

9. Myelodysplastic Syndrome Market, by Treatment Type

• 9.1. Chemotherapy Agents
  • 9.1.1. Cytarabine
  • 9.1.2. Daunorubicin
• 9.2. Hypomethylating Agents
  • 9.2.1. Azacitidine
  • 9.2.2. Decitabine
  • 9.2.3. Guadecitabine
• 9.3. Immunomodulators
  • 9.3.1. Lenalidomide
  • 9.3.2. Pomalidomide
  • 9.3.3. Thalidomide
• 9.4. Supportive Care
  • 9.4.1. Blood Transfusions
  • 9.4.2. Growth Factors
• 9.5. Targeted Therapies
  • 9.5.1. IDH Inhibitors
  • 9.5.2. Luspatercept
  • 9.5.3. Venetoclax

10. Myelodysplastic Syndrome Market, by Route Of Administration

• 10.1. Oral
• 10.2. Subcutaneous
• 10.3. Intravenous

11. Myelodysplastic Syndrome Market, by End User

• 11.1. Home Healthcare
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Myelodysplastic Syndrome Market, by Distribution Channel

• 12.1. Offline
• 12.2. Online

13. Myelodysplastic Syndrome Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Myelodysplastic Syndrome Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Myelodysplastic Syndrome Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AbbVie Inc.
• 17.2. Amgen Inc.
• 17.3. Arrowhead Pharmaceuticals, Inc.
• 17.4. Astellas Pharma Inc.
• 17.5. AstraZeneca plc
• 17.6. Bristol-Myers Squibb Company
• 17.7. Celator Pharmaceuticals, Inc.
• 17.8. Eli Lilly and Company
• 17.9. Gilead Sciences, Inc.
• 17.10. GlaxoSmithKline plc
• 17.11. Incyte Corporation
• 17.12. Jazz Pharmaceuticals plc
• 17.13. Merck & Co., Inc.
• 17.14. MorphoSys AG
• 17.15. Novartis AG
• 17.16. Novimmune SA
• 17.17. Pfizer Inc.
• 17.18. Roche Holding AG
• 17.19. Sanofi S.A.
• 17.20. Takeda Pharmaceutical Company Limited